INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a progressive disease characterized by insulin resistance and decline of b-cell function [1, 2] . Tight glycemic control is one of the cornerstones of effective management of T2DM, as it significantly reduces the risk of microvascular complications and may reduce the impact of macrovascular problems, particularly when achieved early in the disease course [3] [4] [5] .
Based on clinical and experimental studies, the International Diabetes Federation proposed a preferred glycosylated hemoglobin (HbA 1c ) target of B6.5% for the management of T2DM [3] [4] [5] [6] ; experts from the American Diabetes Association and the European Association for the Study of Diabetes issued a statement advocating HbA 1c levels of \7.0%, with stringency of control adapted according to patient-specific features such as age, disease duration, and comorbidities, among others [7] .
This statement recognized that insulin can be an effective component of management strategies to achieve glycemic control, and early initiation of insulin is recommended in patients not meeting HbA 1c targets. The benefits of insulin therapy and the recommendations for its initiation in treatment guidelines have been demonstrated via observational studies and medical insurance database analyses conducted in European and
North American countries [8] [9] [10] . The translation of this to the Asian experience, however, has not specifically been reported. At the same time, the prevalence of T2DM continues to increase at higher rates among Asian countries than in other regions [11] .
Available evidence suggests that insulin utilization in Asia has not markedly changed over the past 10 years [12] [13] [14] , despite changes in treatment guidelines advocating the initiation and intensification of therapy to reach HbA 1c goals. The objective of the First Basal Insulin Evaluation (FINE)-Asia study was to provide details on the real-world initial insulinization in patients with T2DM across Asia, as well as to determine the tolerability and efficacy of basal insulin regimens in this region. This article provides information from post hoc analysis of the FINE-Asia study, which examined variations in baseline characteristics and efficacy and safety endpoints according to the country or region from which patients were enrolled.
METHODS
FINE-Asia was a multinational, prospective, observational study designed to assess the initiation of basal insulin in insulin-naïve patients with T2DM in a real-world clinical setting in Asia. Patients were enrolled from 195 centers/sites across 11 different Asian countries (Bangladesh, China, Hong Kong, India, Indonesia, Korea, Pakistan, Singapore, Taiwan, Thailand, and Vietnam) [15] .
Study Objectives
The FINE-Asia study was designed to evaluate current clinical practice in the treatment of Asian patients with T2DM with inadequate glycemic control on oral antidiabetic drugs (OADs) who have been initiated on basal insulin. The main objective of this post hoc analysis was to examine the baseline characteristics of the study population and to report the findings of the study according to the country or region from which patients were enrolled. The primary efficacy endpoint was the change in HbA 1c from baseline to month 6 after basal insulin initiation. Secondary endpoints included change in fasting blood glucose (FBG) from baseline to month 6, percent of patients achieving target HbA 1c and FBG levels, average insulin doses, and hypoglycemic events.
Patients
From the centers/sites participating in this registry study, male or female patients aged C20 years with T2DM inadequately controlled (HbA 1c C 8%) by OADs, and who, in the opinion of their treating physician, required the initiation of a basal insulin, were eligible for inclusion in the registry.
Patients who received premixed insulin at the start of the registry period, who were prescribed insulin shortly before the start of the registry period (with the exception of acute rescue insulin therapy), or women who were either pregnant or of childbearing potential (not surgically sterile or postmenopausal for less than 2 years) and were not going to use a reliable contraceptive measure for the duration of the study were not included in this registry. In addition, patients with known hypersensitivity to insulin or any excipients of marketed insulin were also excluded from the study.
Study Treatment and Assessments
Basal insulin was initiated with or without concomitant OADs, and no specific protocol between-group comparisons were analyzed using Fisher's exact probability test or chi-square tests as appropriate. All statistical tests were performed using two-tailed tests at a 5% level of significance.
Compliance with ethics guidelines
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation Table 2 ).
Efficacy and Safety by Country at 6 Months
After the addition of basal insulin therapy, significant decreases in HbA 1c (P\0.001) were observed from baseline to month 6 for each individual country/region, with decreases differing significantly between country cohorts (P\0.001), ranging from -1.3% in Taiwan to -2.6% in China and Pakistan ( Fig. 1; Table 3 ). After basal insulin initiation, significant reductions in FBG for each individual country cohort were also observed (P\0.001). In addition, increases in the proportion of patients achieving FBG\110 mg/dL (6.1 mmol/L) were observed at 6 months, although these proportions varied significantly (P\0.001 between each country/region).
Proportions (at 6 months) ranged from 24.7 to 27.6% among the patients in Taiwan, Korea, South-East Asia, and Thailand, and from 43.7 to Table 1 Baseline characteristics of the study population (Fig. 2) .
Wide variations between the cohorts in individual countries/regions were also observed in terms of the proportion of patients achieving HbA 1c \7% at 6 months, with percentages ranging from 7.4% (Taiwan) to 71.5% (China) ( Table 3 ). These variations were also observed with respect to mean insulin dosing, where mean daily dose increases ranged from 0.5 ± 3.1 U/day for the patients in Pakistan to 6.0 ± 8.6 U/day in the Thailand cohort (Table 3) .
After basal insulin initiation, significant differences were observed in the proportion of patients experiencing at least one hypoglycemic event during the 6 months of the study (P\0.001), with the Indian cohort having the Table 3 Mean national differences in glycemic control 6 months after initiation of basal insulin in patients with type 2 diabetes 
DISCUSSION
The Asia-Pacific region comprises more than half of the world's population and has the largest diabetes burden in the world, with hypertension, dyslipidemia, and metabolic syndrome also highly prevalent [16] . India, China, and Pakistan make up three of the top 10 countries having the most people with diabetes, while the prevalence of T2DM in Thailand is 9.8%-double the number forecast by the World Health Organization [17, 18] . An increased risk of death associated with high HbA 1c , age, history of coronary artery disease, and cerebrovascular disease has been reported from the Thailand Diabetic Registry cohort [18] .
As a result, establishing HbA 1c goals and treating patients in these countries, with the intent of rapidly and effectively achieving target HbA 1c levels, is crucial to successful glycemic control.
Data from this FINE-Asia study show widely varying degrees of glycemic control in patients with T2DM, depending on country of residence.
Of the country cohorts observed, the highest percentage of patients reaching target HbA 1c levels of \7.0% at study end (71.5%) was observed in Chinese patients. Along with India, China had the joint lowest mean HbA 1c levels (9.4%) at baseline, yet only 43.0% of Indian patients with T2DM reached target HbA 1c levels of \7.0% at study end. It should be noted that Chinese patients had the shortest duration of diabetes (6.3 years) and OAD use (5.8 years) of any country studied, including India. In line with findings from previous studies [19] , as well as the Chinese Guidelines for Prevention and Treatment of Diabetes, Chinese patients with T2DM appear to benefit from earlier initiation of treatment. Rates of hypoglycemia, however, were highest (27.3%) in Chinese patients and lowest among those in India (7.1%). Although hypoglycemia is a well-reported side effect of insulin treatment [20] , these findings highlight the importance of monitoring glucose levels upon initiation of basal insulin treatment, particularly when an early, aggressive approach to glycemic control is undertaken. While the reasoning for the disparity in hypoglycemia rates cannot be fully elucidated, duration of diabetes (6.3 vs. [21] . This is particularly important in diabetes, where both physicianand patient-based decisions and practice can impact outcomes. Multinational observational studies such as A1chieve (NCT00869908) [22] , IMPROVE (NCT00659282) [23] , PREDICTIVE (NCT00659295) [24] , and PRESENT [25] , among others, have utilized real-world clinical practice as the basis for observing and recommending management approach adjustments to optimize glycemic control in the context of insulin initiation. Many of these studies, such as A1chieve and CREDIT [26] [27] [28] [29] suggest that the use of insulin glargine is associated with greater glycemic control than insulin detemir at the same dose. 
